{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:37:08Z","timestamp":1794256628168,"version":"4.9.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Clinical Specialty Scientific Research Project","award":["Z2023142"],"award-info":[{"award-number":["Z2023142"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02921-9","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T16:14:49Z","timestamp":1754496889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Glutamate-cysteine ligase as a diagnostic biomarker and therapeutic target in Parkinson's disease: a multi-omics and experimental study"],"prefix":"10.1186","volume":"30","author":[{"given":"Xuzhao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"2921_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2741\/s415","volume":"6","author":"JM Beitz","year":"2014","unstructured":"Beitz JM. Parkinson\u2019s disease: a review. Front Biosci (Schol Ed). 2014;6:65\u201374. https:\/\/doi.org\/10.2741\/s415.","journal-title":"Front Biosci (Schol Ed)"},{"key":"2921_CR2","doi-asserted-by":"publisher","first-page":"564","DOI":"10.2174\/1874467216666221103121135","volume":"16","author":"M Mamelak","year":"2023","unstructured":"Mamelak M. The treatment of Parkinson\u2019s disease with sodium oxybate. Curr Mol Pharmacol. 2023;16:564\u201379. https:\/\/doi.org\/10.2174\/1874467216666221103121135.","journal-title":"Curr Mol Pharmacol"},{"key":"2921_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrn.2016.178","volume":"18","author":"DJ Surmeier","year":"2017","unstructured":"Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017;18:101\u201313. https:\/\/doi.org\/10.1038\/nrn.2016.178.","journal-title":"Nat Rev Neurosci"},{"key":"2921_CR4","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C. Parkinson\u2019s disease. Lancet. 2021;397:2284\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(21)00218-X.","journal-title":"Lancet"},{"key":"2921_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"GBDN Collaborators","year":"2019","unstructured":"Collaborators GBDN. Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459\u201380. https:\/\/doi.org\/10.1016\/S1474-4422(18)30499-X.","journal-title":"Lancet Neurol"},{"key":"2921_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8:S3\u20138. https:\/\/doi.org\/10.3233\/JPD-181474.","journal-title":"J Parkinsons Dis"},{"key":"2921_CR7","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/WCO.0000000000001166","volume":"36","author":"R Wang","year":"2023","unstructured":"Wang R, Shih LC. Parkinson\u2019s disease - current treatment. Curr Opin Neurol. 2023;36:302\u20138. https:\/\/doi.org\/10.1097\/WCO.0000000000001166.","journal-title":"Curr Opin Neurol"},{"key":"2921_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","volume":"19","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson\u2019s disease. Lancet Neurol. 2020;19:170\u20138. https:\/\/doi.org\/10.1016\/S1474-4422(19)30287-X.","journal-title":"Lancet Neurol"},{"key":"2921_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-pathmechdis-031521-034145","volume":"18","author":"H Ye","year":"2023","unstructured":"Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Genetics and pathogenesis of Parkinson\u2019s syndrome. Annu Rev Pathol. 2023;18:95\u2013121. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-031521-034145.","journal-title":"Annu Rev Pathol"},{"key":"2921_CR10","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.cell.2020.08.004","volume":"182","author":"R Watanabe","year":"2020","unstructured":"Watanabe R, et al. The in situ structure of Parkinson\u2019s disease-linked LRRK2. Cell. 2020;182:1508\u201318. https:\/\/doi.org\/10.1016\/j.cell.2020.08.004.","journal-title":"Cell"},{"key":"2921_CR11","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science. 1997;276:2045\u20137. https:\/\/doi.org\/10.1126\/science.276.5321.2045.","journal-title":"Science"},{"key":"2921_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-023-00676-7","volume":"18","author":"MT Henrich","year":"2023","unstructured":"Henrich MT, Oertel WH, Surmeier DJ, Geibl FF. Mitochondrial dysfunction in Parkinson\u2019s disease - a key disease hallmark with therapeutic potential. Mol Neurodegener. 2023;18:83. https:\/\/doi.org\/10.1186\/s13024-023-00676-7.","journal-title":"Mol Neurodegener"},{"key":"2921_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","volume":"36","author":"DK Simon","year":"2020","unstructured":"Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med. 2020;36:1\u201312. https:\/\/doi.org\/10.1016\/j.cger.2019.08.002.","journal-title":"Clin Geriatr Med"},{"key":"2921_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pneurobio.2013.04.004","volume":"106\u2013107","author":"SR Subramaniam","year":"2013","unstructured":"Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease. Prog Neurobiol. 2013;106\u2013107:17\u201332. https:\/\/doi.org\/10.1016\/j.pneurobio.2013.04.004.","journal-title":"Prog Neurobiol"},{"key":"2921_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12974-021-02250-8","volume":"18","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, et al. NAD(+) improves cognitive function and reduces neuroinflammation by ameliorating mitochondrial damage and decreasing ROS production in chronic cerebral hypoperfusion models through Sirt1\/PGC-1alpha pathway. J Neuroinflammation. 2021;18:207. https:\/\/doi.org\/10.1186\/s12974-021-02250-8.","journal-title":"J Neuroinflammation"},{"key":"2921_CR16","doi-asserted-by":"publisher","first-page":"e18761429383749","DOI":"10.2174\/0118761429383749250312082958","volume":"17","author":"ZY Zhi","year":"2024","unstructured":"Zhi ZY, Wang PC. The mitochondrial targeting drug SkQ1 attenuates the progression of post- traumatic osteoarthritis through suppression of mitochondrial oxidative stress. Curr Mol Pharmacol. 2024;17:e18761429383749. https:\/\/doi.org\/10.2174\/0118761429383749250312082958.","journal-title":"Curr Mol Pharmacol"},{"key":"2921_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson\u2019s disease. Lancet. 2024;403:293\u2013304. https:\/\/doi.org\/10.1016\/S0140-6736(23)01478-2.","journal-title":"Lancet"},{"key":"2921_CR18","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/brain\/awad388","volume":"147","author":"Y Chu","year":"2024","unstructured":"Chu Y, et al. Nigrostriatal tau pathology in Parkinsonism and Parkinson\u2019s disease. Brain. 2024;147:444\u201357. https:\/\/doi.org\/10.1093\/brain\/awad388.","journal-title":"Brain"},{"key":"2921_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1212\/WNL.0000000000000653","volume":"83","author":"AH Rajput","year":"2014","unstructured":"Rajput AH, Rajput A. Accuracy of Parkinson disease diagnosis unchanged in 2 decades. Neurology. 2014;83:386\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000000653.","journal-title":"Neurology"},{"key":"2921_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol. 2021;20:385\u201397. https:\/\/doi.org\/10.1016\/S1474-4422(21)00030-2.","journal-title":"Lancet Neurol"},{"key":"2921_CR21","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley JM, Lees AJ. Ageing and Parkinson\u2019s disease: substantia Nigra regional selectivity. Brain. 1991;114:2283\u2013301. https:\/\/doi.org\/10.1093\/brain\/114.5.2283.","journal-title":"Brain"},{"key":"2921_CR22","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1093\/brain\/awt192","volume":"136","author":"JH Kordower","year":"2013","unstructured":"Kordower JH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease. Brain. 2013;136:2419\u201331. https:\/\/doi.org\/10.1093\/brain\/awt192.","journal-title":"Brain"},{"key":"2921_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2174\/0115734129304769240403075839","volume":"20","author":"X Huang","year":"2024","unstructured":"Huang X, et al. Determination of ketamine and palmatine in rat plasma by UHPLC-MS\/MS and their pharmacokinetic interaction. Curr Pharm Anal. 2024;20:224\u20139. https:\/\/doi.org\/10.2174\/0115734129304769240403075839.","journal-title":"Curr Pharm Anal"},{"key":"2921_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/978-1-0716-0239-3_19","volume":"2104","author":"A Karnovsky","year":"2020","unstructured":"Karnovsky A, Li S. Pathway analysis for targeted and untargeted metabolomics. Methods Mol Biol. 2020;2104:387\u2013400. https:\/\/doi.org\/10.1007\/978-1-0716-0239-3_19.","journal-title":"Methods Mol Biol"},{"key":"2921_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12906-019-2738-7","volume":"20","author":"T Wang","year":"2020","unstructured":"Wang T, et al. Neuroprotective effects of Danshensu on rotenone-induced Parkinson\u2019s disease models in vitro and in vivo. BMC Complement Med Ther. 2020;20:20. https:\/\/doi.org\/10.1186\/s12906-019-2738-7.","journal-title":"BMC Complement Med Ther"},{"key":"2921_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228765","author":"CO Reichert","year":"2020","unstructured":"Reichert CO, et al. Ferroptosis mechanisms involved in neurodegenerative diseases. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21228765.","journal-title":"Int J Mol Sci"},{"key":"2921_CR27","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1007\/s12640-022-00558-8","volume":"40","author":"J Shao","year":"2022","unstructured":"Shao J, Liu X, Lian M, Mao Y. Citronellol prevents 6-OHDA-induced oxidative stress, mitochondrial dysfunction, and apoptosis in Parkinson disease model of SH-SY5Y cells via modulating ROS-NO, MAPK\/ERK, and PI3K\/Akt signaling pathways. Neurotox Res. 2022;40:2221\u201337. https:\/\/doi.org\/10.1007\/s12640-022-00558-8.","journal-title":"Neurotox Res"},{"key":"2921_CR28","doi-asserted-by":"publisher","first-page":"155993","DOI":"10.1016\/j.phymed.2024.155993","volume":"134","author":"PX Yang","year":"2024","unstructured":"Yang PX, et al. Longxuetongluo Capsule alleviate ischemia\/reperfusion induced cardiomyocyte apoptosis through modulating oxidative stress and mitochondrial dysfunction. Phytomedicine. 2024;134:155993. https:\/\/doi.org\/10.1016\/j.phymed.2024.155993.","journal-title":"Phytomedicine"},{"key":"2921_CR29","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1038\/s41467-024-48330-0","volume":"15","author":"D Jiang","year":"2024","unstructured":"Jiang D, et al. IRE1alpha determines ferroptosis sensitivity through regulation of glutathione synthesis. Nat Commun. 2024;15:4114. https:\/\/doi.org\/10.1038\/s41467-024-48330-0.","journal-title":"Nat Commun"},{"key":"2921_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22095010","author":"K Aoyama","year":"2021","unstructured":"Aoyama K. Glutathione in the Brain. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22095010.","journal-title":"Int J Mol Sci"},{"key":"2921_CR31","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.neubiorev.2020.10.004","volume":"120","author":"G Bj\u00f8rklund","year":"2021","unstructured":"Bj\u00f8rklund G, Peana M, Maes M, Dadar M, Severin B. The glutathione system in Parkinson\u2019s disease and its progression. Neurosci Biobehav Rev. 2021;120:470\u20138. https:\/\/doi.org\/10.1016\/j.neubiorev.2020.10.004.","journal-title":"Neurosci Biobehav Rev"},{"key":"2921_CR32","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41467-020-14788-x","volume":"11","author":"Y Wei","year":"2020","unstructured":"Wei Y, et al. Pyridoxine induces glutathione synthesis via PKM2-mediated Nrf2 transactivation and confers neuroprotection. Nat Commun. 2020;11:941. https:\/\/doi.org\/10.1038\/s41467-020-14788-x.","journal-title":"Nat Commun"},{"key":"2921_CR33","doi-asserted-by":"publisher","first-page":"965064","DOI":"10.3389\/fmolb.2022.965064","volume":"9","author":"H Ma","year":"2022","unstructured":"Ma H, Dong Y, Chu Y, Guo Y, Li L. The mechanisms of ferroptosis and its role in Alzheimer\u2019s disease. Front Mol Biosci. 2022;9:965064. https:\/\/doi.org\/10.3389\/fmolb.2022.965064.","journal-title":"Front Mol Biosci"},{"key":"2921_CR34","doi-asserted-by":"publisher","first-page":"101263","DOI":"10.1016\/j.arr.2021.101263","volume":"67","author":"PA Dionisio","year":"2021","unstructured":"Dionisio PA, Amaral JD, Rodrigues CMP. Oxidative stress and regulated cell death in Parkinson\u2019s disease. Ageing Res Rev. 2021;67:101263. https:\/\/doi.org\/10.1016\/j.arr.2021.101263.","journal-title":"Ageing Res Rev"},{"key":"2921_CR35","doi-asserted-by":"publisher","first-page":"e53234","DOI":"10.15252\/embr.202153234","volume":"23","author":"L Qu","year":"2022","unstructured":"Qu L, et al. Lysosomal K(+) channel TMEM175 promotes apoptosis and aggravates symptoms of Parkinson\u2019s disease. EMBO Rep. 2022;23:e53234. https:\/\/doi.org\/10.15252\/embr.202153234.","journal-title":"EMBO Rep"},{"key":"2921_CR36","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1016\/j.scib.2023.10.021","volume":"68","author":"S Tan","year":"2023","unstructured":"Tan S, et al. Targeted clearance of mitochondria by an autophagy-tethering compound (ATTEC) and its potential therapeutic effects. Sci Bull (Beijing). 2023;68:3013\u201326. https:\/\/doi.org\/10.1016\/j.scib.2023.10.021.","journal-title":"Sci Bull (Beijing)"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02921-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02921-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02921-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T16:14:50Z","timestamp":1754496890000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02921-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2921"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02921-9","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the First People's Hospital of Changde City (2024-094-01). The animal study was approved by the Ethics Committee of Xiangya Hospital of Central South University (Approval No.2024092910).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"721"}}